US FDA says its upcoming accreditation scheme pilot to streamline the agency's review of companies' conformance to standards is an important part of the effort to modernize and globally harmonize pre-market reviews. But questions about what manufacturers will tangibly gain from the program, what the costs will be and the challenges of incorporating specific standards still need to be answered.
The agency convened a workshop May 22-23 at its Maryland headquarters to discuss the Accreditation Scheme for Conformity Assessment (ASCA) for medical devices. The ambitious program was hatched in the most recent MDUFA IV user-fee negotiations, and FDA has committed to getting it off the ground by fiscal year 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?